Trials / Completed
CompletedNCT04237831
A Study to Evaluate the Pharmacokinetics (Drug Levels and Metabolism), Safety, and Tolerability of BMS-986259 in Participants With Various Levels of Kidney Function
A Phase 1, Open-Label, Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986259 in Participants With Varying Degrees of Renal Function
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
A study to evaluate the drug effect, safety, and tolerability of BMS-986259 in participants with different levels of kidney function
Detailed description
Recruitment temporarily on hold due to COVID-19
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986259 | Specified Dose on Specified Days |
Timeline
- Start date
- 2020-02-26
- Primary completion
- 2021-07-16
- Completion
- 2021-07-16
- First posted
- 2020-01-23
- Last updated
- 2021-09-24
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04237831. Inclusion in this directory is not an endorsement.